Journal of Hepatology
Volume 53, Issue 2 , Pages 313-317 , August 2010

In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival

Received 15 November 2009 ,Revised 21 February 2010 ,Accepted 23 February 2010.

References 

  1. Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, et al. Primary sclerosing cholangitis – a review of its clinical features, cholangiography and hepatic histology. Gut. 1980;21:870–877
  2. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200–206
  3. Farrant MJ, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710–1717
  4. Lee Y-M, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924–933
  5. Broome U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–615
  6. Beuers U, Spengler U, Kruis W, Aydemir Ü, Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology. 1992;16:707–714
  7. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo-controlled study period. J Hepatol. 1994;20:57–64
  8. Lindor KD, the Mayo PSC/UDCA study group . Ursodiol for the treatment of primary sclerosing cholangitis. N Engl J Med. 1997;336:691–695
  9. Mitchell SA, Bansi DS, Hunt N, von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled study. Gastroenterology. 2001;121:900–907
  10. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1558–1562
  11. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hulcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis. A five year multicenter randomized controlled study.. Gastroenterology. 2005;129:1464–1472
  12. Lindor KD, Knowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:671–673
  13. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilatation of major duct stenoses in primary sclerosing cholangitis. An 8 years prospective study. J Hepatol. 1997;26:560–566
  14. Stiehl A, Rudolph G, Klöters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–156
  15. Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149–155
  16. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Sem Liv Dis. 2006;26:31–41
  17. Ghazale A, Chari St, Zhang L, Smyrk CT, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–715
  18. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology. 2004;40:693–698
  19. Gotthardt D, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilatation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc. 2010;71:527–534
  20. Stiehl A. Primary sclerosing cholangitis: the role of endoscopic therapy. Sem Liv Dis. 2006;26:62–68
  21. Kulaksiz H, Rudolph G, Kloeters-Plachky P, Sauer P, Geiss H, Stiehl A. Biliary Candida infections in primary sclerosing cholangitis. J Hepatol. 2006;45:711–716
  22. Woolson RF. Rank tests and a one-sample log rank test for comparing observed survival data to a standard population. Biometrics. 1981;37:687–696
  23. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982;69:553–566
  24. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2007;19:487–491
  25. Olsson R, Björnsson E, Bäckman L, Friman S, Höckerstedt K, Kaijser B, et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol. 1998;28:426–432
  26. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 2006;18:69–74
  27. Broome U, Löfberg R, Veress B, Erikson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22:1404–1408
  28. Claessen MMH, Vleggaar FP, Tytgat MAJ, Siersema PD, Van Buuren HR. High life-time risk of cancer in primary sclerosing cholangitis. J Hepatology. 2009;50:158–164
  29. Tung BY, Edmond MJ, Haggitt RC, Bronner MP, Kimmey MB, Knowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in cholangitis. Ann Intern Med. 2001;134:89–95
  30. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–893
  31. Ludwig J, Barham SS, LaRusso RF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology. 1981;1:632–640
  32. Rabinovitz M, Gavaler JS, Schade RR, Dindzans VJ, Chien MC, Van Thiel DH. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease?. Hepatology. 1990;11:7–11

PII: S0168-8278(10)00322-3

doi: 10.1016/j.jhep.2010.02.030

Journal of Hepatology
Volume 53, Issue 2 , Pages 313-317 , August 2010

Article Tools

* Image Usage & Resolution